Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Corren J, Garcia Gil E, Griffiths JM, Parnes JR, et al. Ann Allergy Asthma Immunol 2020 Oct 23. pii: S1081-1206(20)31108.

Read + Share

Amedeo Smart

Independent Medical Education

Corren J, Garcia Gil E, Griffiths JM, Parnes JR, et al. Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. Ann Allergy Asthma Immunol 2020 Oct 23. pii: S1081-1206(20)31108.
PMID: 33169672